Trial · NCT04105231
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
NCT04105231, Phase 2, Active not recruiting, Lone Baandrup
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use. Trials, record NCT04105231. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04105231
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
- NCT number
- NCT04105231
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Lone Baandrup
- Conditions
- Dual Diagnosis
- Interventions
- Cannabidiol, Risperidone
- First posted
- 2019-09-26
- Last updated
- 2026-01-27
- Other registries' IDs
- eudract:2018-004893-84
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Psychotic symptoms | 7 weeks follow-up | Positive and Negative Syndrome Scale (PANSS) positive subscale, range 7-49. A measure of symptom severity. Higher values are worse. |
| Secondary | Cannabis cessation (no use of cannabis within the past two weeks) (for current cannabis users at baseline) | 7 weeks follow-up | Timeline follow back method |
| Secondary | Cannabis use by self-reported days of cannabis use per week, since last study visit. | 7 weeks follow-up | Timeline follow back method |
| Secondary | Amount of cannabis use per day, self-reported, since last study visit. | 7 weeks follow-up | PSYSCAN cannabis questionnaire# 6-8 |
| Secondary | Response | 7 weeks follow-up | Response defined by PANSS total 25 percentile changes |
| Secondary | Remission | 7 weeks follow-up | Symptomatic remission is defined according to the Andreasen et al remission criteria. The criteria define symptomatic remission as a rating of no more than mild in four core positive and four core negative symptoms on the Positive and Negative Syndrome Scale (P1, P2 P3, N1, N4, N6, G5, G9,) that is sustained for ≥6 months. Because of the duration of this study, the requirement of 6 month will not be considered. |
| Secondary | Global illness severity | 7 weeks follow-up | Global illness severity is assessed with the Clinical Global Impression Scale (CGI). We will use the severity (CGI-S) at baseline and improvement (CGI-I) scores of the CGI at the following visits. Response will be defined as much improved or better on the CGI-I. The main item 'severity of illness' is measured on a 7-point Likert scale (from 1 'normal, not at all ill' to 7 'among the most extremely ill patients'). |
| Secondary | Psychosocial functioning | 7 weeks follow-up | Personal and Social Performance Scale (PSP). Higher is better, range 1-100. |
| Secondary | Neurocognitive functioning | 7 weeks follow-up | Brief Assessment of Cognition in Schizophrenia (BACS). Neurocognitive Test Battery. One composite score and six subscales. |
| Secondary | Subjective well-being | 7 weeks follow-up | Subjective Well-being under Neuroleptics Scale (SWN). A measure of health-related quality of life. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34391393 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04105231
GET https://conductscience.org/api/trials/v1/NCT04105231/registered